Clinical Trials Logo

CD79B Gene Mutation clinical trials

View clinical trials related to CD79B Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04994626 Not yet recruiting - Relapse Clinical Trials

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ibrutinib Combined With Rituximab in Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies.

NCT ID: NCT04668365 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Start date: December 25, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of zanubrutinib combined with standard chemotherapy in the treatment for patients with diffuse large B cell lymphoma and CD79A/CD79B genetic abnormality.